Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E34.49 EPS (ttm)1.64 Insider Own0.04% Shs Outstand2.77B Perf Week3.32%
Market Cap156.43B Forward P/E15.05 EPS next Y3.75 Insider Trans-11.20% Shs Float2.77B Perf Month0.14%
Income4.62B PEG10.44 EPS next Q0.91 Inst Own74.70% Short Float1.00% Perf Quarter12.33%
Sales39.39B P/S3.97 EPS this Y-61.60% Inst Trans-0.41% Short Ratio3.15 Perf Half Y7.28%
Book/sh15.79 P/B3.57 EPS next Y0.89% ROA4.60% Target Price61.55 Perf Year-2.33%
Cash/sh4.67 P/C12.09 EPS next 5Y3.31% ROE10.20% 52W Range44.52 - 59.67 Perf YTD7.69%
Dividend1.84 P/FCF26.88 EPS past 5Y41.50% ROI6.40% 52W High-5.50% Beta0.68
Dividend %3.26% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin62.80% 52W Low26.66% ATR0.79
Employees68000 Current Ratio1.60 Sales Q/Q-1.20% Oper. Margin18.20% RSI (14)63.29 Volatility1.21% 1.35%
OptionableYes Debt/Eq0.59 EPS Q/Q20.60% Profit Margin11.70% Rel Volume0.64 Prev Close56.57
ShortableYes LT Debt/Eq0.54 EarningsMay 05 BMO Payout110.40% Avg Volume8.79M Price56.39
Recom2.50 SMA203.00% SMA503.11% SMA2007.56% Volume5,606,100 Change-0.32%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
May-27-16 07:46AM  Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union Business Wire
May-26-16 07:47PM  U.S. sees first case of bacteria resistant to all antibiotics Reuters
10:43AM  Cancer Immunotherapies Take Center Stage in Pre-ASCO Abstract Releases at Motley Fool
09:09AM  Pfizer Offers Hope For Lower-Priced Cancer Drug Combos at Forbes
08:08AM  Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets Business Wire
May-25-16 07:13PM  Market Indexes Higher With Volatility Lower
04:01PM  The 4 Stocks That Boosted the DJIA on Wednesday at 24/7 Wall St.
08:15AM  Short Sellers Take Mixed Stance on Major Pharma at 24/7 Wall St.
05:30AM  What To Look For In a Successful Money Manager Today: Mindsets and Beliefs
03:51AM  Merck KGaA :MRK-DE: Earnings Analysis: Q1, 2016 By the Numbers : May 25, 2016
May-24-16 02:35PM  Merck Announces Third-Quarter 2016 Dividend Business Wire
11:39AM  Monsanto: A 'Once in a Lifetime Opportunity?' at
08:00AM  Merck to Present at the UBS Global Healthcare Conference Business Wire
06:19AM  MSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO (fluralaner) Spot-On Solution for Cats and Dogs Business Wire
May-23-16 11:40PM  [$$] Bayer Makes $62 Billion Bid for Monsanto at The Wall Street Journal
07:16PM  [$$] Germany's Bayer Offers $62 Billion in Cash for Monsanto at The Wall Street Journal
12:52PM  Rlypsa Stock Pops on New Data and a Huge Risk
12:15PM  Domini's Highest Performing Mutual Fund Since Inception (DSEFX) at Investopedia
09:00AM  Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to High-Quality Cancer Care in Underserved Communities in the United States Business Wire
05:55AM  A Rudderless Market
May-22-16 07:00PM  China's drugs watchdog struggles as senior staff lured away by industry Reuters
May-20-16 11:08AM  Gilead Sciences: Where Do We Go From Here? at
10:33AM  Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
10:05AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
May-19-16 03:53PM  Biggest German Deals: Bayer Hopes to Dodge Daimler-Chrysler Fate
11:24AM  Will These Game-Changing Cancer Treatments Hit the Market in 2016? at Motley Fool
05:33AM  Fed Should Not Raise Rates Now
04:12AM  We Will Deliver Sigma Synergies For 2016, Vows Merck CFO
May-18-16 07:07PM  Will Mercks Recent New Developments Make a Difference?
07:07PM  The Reasons behind Mercks Improving Profitability
06:07PM  New Hope for Melanoma Patients at MarketWatch
05:19PM  New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting Business Wire
05:09PM  Amgen Researchers Find Gene That Reduces Heart Attack Risk at Forbes
05:00PM  Merck, Bristol drugs show longer survival for deadly cancers
05:00PM  German Merck, Pfizer immunotherapy shows promise in rare skin cancer
May-16-16 10:07AM  Whats Driving Mercks Animal Health Segment?
09:45AM  Merck To Present New And Updated Data On KEYTRUDA
08:07AM  Why Is Remicade Driving Down Mercks Performance?
08:00AM  New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer Business Wire
May-14-16 04:14PM  Kahn Brothers Top Stock Picks: Merck & Co. Inc. (MRK) Overtakes Citigroup Inc. (C) as Top Holding at Insider Monkey
01:04PM  MERCK & CO., INC. Financials
May-13-16 05:42PM  5 Surprising Comments in Merck's Quarterly Conference Call at Motley Fool
03:07PM  How Is Gardasil Driving Mercks Vaccines Business?
May-12-16 10:59AM  Merck To Present Final Stage Data On Investigational Medicines Ertugliflozin And MK-1293 Benzinga
10:09AM  Januvia and Janumet: Mercks Blockbuster Diabetes Drugs Market Realist
08:30AM  Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association Business Wire
08:21AM  Why I Think Pfizer Is a Better Buy Than Merck & Co. at Motley Fool
05:06AM  Pfizers Pipeline and Corporate Developments in 2016 Market Realist
01:04AM  Mercks Valuation Cheat Sheet for 1Q16 Market Realist
May-11-16 04:37PM  Retailers lead a broad decline in stocks as Macy's plunges AP
04:31PM  Why Endo International plc Investigated a Lower Price at Motley Fool
03:48PM  What Factors Are Impacting Mercks Growth? Market Realist
03:47PM  Mercks Valuation Cheat Sheet for Fiscal 1Q16 Market Realist
12:58PM  DOJ Investigation Has Little Impact on Pharmas' Share Prices at TheStreet
11:14AM  Global Pharma Players Likely to Flock to Medivation at TheStreet
09:07AM  Pfizers 1Q16 Earnings: Profitability and Financial Guidance Market Realist
08:45AM  Major Pharma Short Interest Continues to Recede at 24/7 Wall St.
12:14AM  [$$] U.S. Investigates Drugmaker Contracts With Pharmacy-Benefit Managers at The Wall Street Journal
May-10-16 09:35PM  U.S. probes contracts between drugmakers, pharmacy benefit managers Reuters
07:02PM  Cramer: The World Is Gunning for Valeant at TheStreet
05:14PM  US probes contracts between drugmakers, pharmacy benefit managers Reuters
02:30PM  U.S. investigates Merck, J&J and Endo over pharmacy-benefit contracts at MarketWatch
10:50AM  [$$] Three Big Pharma Stocks Headed Higher at
07:30AM  Boston drug firm's shares slump due to job cuts, cash shortage at American City Business Journals
May-09-16 07:25PM  U.S. Stocks Trade Flat at Start of Week Gurufocus
05:26PM  MERCK & CO., INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
05:04PM  Keytruda: The Rising Hope of Merck & Co. Market Realist
12:12PM  Merck & Co., Inc. :MRK-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
10:47AM  [$$] Pfizer to trial triple-combination cancer treatment at Financial Times
10:18AM  Gilead Sciences: A Black Box of Uncertainty? at
10:08AM  Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut at Motley Fool
08:47AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : May 9, 2016 at Capital Cube
05:39AM  Ever Grinding Higher Economy and Financial Markets Yahoo Finance Contributors
May-08-16 06:48PM  Startling Disclosure in Relypsa's Filings Reveal a Possible Sanofi Takeover Yahoo Finance Contributors
03:57PM  Market Indexes Flat as Economic Indicators Still Point Lower Gurufocus
03:01PM  Profit-Taking Clobbers Advaxis, Inc. in April Despite Positive PR at Motley Fool
12:17PM  3 Growth Dividend Stocks to Buy in May at Motley Fool
May-06-16 04:43PM  Investors Aim For Stable Growers That Can Thrive Despite Volatility at Investor's Business Daily
12:05PM  How Do Eli Lillys Valuation Multiples Compare to Peers? Market Realist
11:49AM  Dow 30 Stock Roundup: Pfizer, Merck, Exxon Beat on Earnings, Chevron Posts Loss Zacks
11:12AM  Solid Q1 Earnings Fail to Boost Pharma ETFs Zacks
10:10AM  Stock Market News for May 06, 2016 Zacks
05:56AM  Merck CEO: Were on the Hunt for Deals in 2016 at Fortune
12:09AM  Fading Oil Rally Keeps a Lid on U.S. Stocks at The Wall Street Journal
May-05-16 07:49PM  Fading Oil Rally Keeps Lid on U.S. Stocks at The Wall Street Journal
05:30PM  Stocks End Little Changed; Earnings, Oil Eyed Morningstar
05:13PM  Charts are bullish for health care: Technician Yahoo Finance
05:03PM  S&P 500, Dow end little changed ahead of jobs report; Nasdaq logs a loss at MarketWatch
04:01PM  The 4 Stocks That Edged the DJIA Down on Thursday at 24/7 Wall St.
03:16PM  [$$] Merck: Good Time to Buy at
02:30PM  Edited Transcript of MRK earnings conference call or presentation 5-May-16 12:00pm GMT Thomson Reuters StreetEvents
01:25PM  Merck beats 1Q profit views with tight cost controls AP
01:10PM  Healthy biotech M&A? CNBC
12:53PM  Why Merck, Whole Foods Market & Other Stocks Are in Spotlight Today? at Insider Monkey
12:41PM  Regeneron Up As Eylea Beats Views; Merck Down As Lead Drugs Slip at Investor's Business Daily
12:20PM  Stocks Rise; Earnings, Oil Eyed Morningstar
12:01PM  7 Figures That Sum Up Merck & Co.'s First Quarter at Motley Fool
10:40AM  [$$] Merck Revenue Falls on Generic Competition at The Wall Street Journal
09:45AM  Pullback Among Chip Makers Is Latest Reason to Doubt the Rally --- Morning MoneyBeat at The Wall Street Journal
09:31AM  Stocks to Watch: Alibaba, Regeneron, Merck, AmerisourceBergen at The Wall Street Journal
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM